{"id":"W2948104235","doi":"10.1056/nejmoa1902226","title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1112,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Janssen Pharmaceuticals; National Center for Advancing Translational Sciences; Genentech; Dexcom; National Institutes of Health; Servier; Zafgen; MannKind Corporation; MacroGenics; Immune Tolerance Network; American Diabetes Association; Massachusetts Medical Society; Novo Nordisk; Intarcia Therapeutics; Juvenile Diabetes Research Foundation United Kingdom; Yale University; Esperion Therapeutics; GlaxoSmithKline; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi","keywords":"Medicine; Diabetes mellitus; Placebo; Internal medicine; Hazard ratio; Type 2 diabetes; Type 1 diabetes; Randomization; Confidence interval; Insulin; Gastroenterology; Randomized controlled trial; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005653995,0.0001052869,0.0002708251,0.00007262795,0.00002834556,0.000005802475,0.0001292126,0.00009140391,0.00007096145],"category_scores_gemma":[0.000303007,0.00007392753,0.00005567291,0.00008383528,0.00003936503,0.000008632918,0.00001867885,0.0001224818,0.000003805075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001373162,"about_ca_system_score_gemma":0.00005782266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001564262,"about_ca_topic_score_gemma":0.00002319001,"domain_scores_codex":[0.9992104,0.00007004006,0.0002691675,0.0001345507,0.0001240027,0.0001918839],"domain_scores_gemma":[0.9993412,0.00006388738,0.000257491,0.0001287521,0.0001038346,0.0001048309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002716664,0.00005639777,0.6302724,0.000014429,0.00008732959,0.000002180374,0.0001599683,0.0002060913,0.3532555,0.00001670312,0.002651028,0.01300638],"study_design_scores_gemma":[0.1153122,0.01806367,0.5568125,0.0005713756,0.0002719639,0.00002878082,0.0008432816,0.0006433715,0.03797446,0.001976954,0.2668828,0.0006185793],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952082,0.003284134,0.00004899714,0.0004790775,0.0003500626,0.0001091067,0.000006444441,0.000002064446,0.0005118884],"genre_scores_gemma":[0.9970732,0.001273924,0.0001787392,0.0001484905,0.0007739354,4.771969e-7,0.00005566152,0.00001492512,0.0004806732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.315281,"threshold_uncertainty_score":0.3014677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008130474669345241,"score_gpt":0.2819474254084911,"score_spread":0.2738169507391459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}